Short Interest in Ziopharm Oncology Inc. (ZIOP) Drops By 3.8%
Ziopharm Oncology Inc. (NASDAQ:ZIOP) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 37,427,735 shares, a decrease of 3.8% from the August 31st total of 38,909,971 shares. Based on an average daily trading volume, of 1,734,211 shares, the short-interest ratio is presently 21.6 days. Currently, 31.7% of the shares of the company are short sold.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research note on Tuesday, August 16th. Griffin Securities restated a “buy” rating and issued a $21.00 price objective on shares of Ziopharm Oncology in a research note on Monday, August 15th. Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research note on Wednesday, August 10th. Mizuho restated a “neutral” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Ziopharm Oncology in a research note on Monday, July 18th. Finally, Raymond James Financial Inc. assumed coverage on Ziopharm Oncology in a research note on Thursday, June 2nd. They issued a “market perform” rating on the stock. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.75.
Ziopharm Oncology (NASDAQ:ZIOP) opened at 5.91 on Thursday. The firm’s market cap is $771.23 million. The stock has a 50 day moving average price of $5.47 and a 200 day moving average price of $6.43. Ziopharm Oncology has a 52-week low of $4.45 and a 52-week high of $14.93.
Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.90. The business earned $1.70 million during the quarter, compared to analysts’ expectations of $1.52 million. Ziopharm Oncology had a negative return on equity of 100.01% and a negative net margin of 2,292.26%. Ziopharm Oncology’s revenue for the quarter was up 525.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.11) EPS. Equities analysts predict that Ziopharm Oncology will post ($1.34) earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the company. Stratos Wealth Partners LTD. purchased a new stake in Ziopharm Oncology during the first quarter worth approximately $102,000. Advisor Group Inc. purchased a new stake in Ziopharm Oncology during the second quarter worth approximately $105,000. Royal Bank of Canada boosted its stake in Ziopharm Oncology by 18.8% in the second quarter. Royal Bank of Canada now owns 19,235 shares of the biotechnology company’s stock worth $105,000 after buying an additional 3,046 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in Ziopharm Oncology by 4.8% in the second quarter. Oppenheimer & Co. Inc. now owns 20,100 shares of the biotechnology company’s stock worth $110,000 after buying an additional 919 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Ziopharm Oncology during the second quarter worth approximately $114,000. Institutional investors and hedge funds own 44.95% of the company’s stock.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Receive News & Stock Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related stocks with our FREE daily email newsletter.